These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 36819490)

  • 1. The combined effect and mechanism of antiangiogenic drugs and PD-L1 inhibitor on cell apoptosis in triple negative breast cancer.
    Li J; Zhang D; Liu Z; Wang Y; Li X; Wang Z; Liang G; Yuan X; Li Y; Komorowski AL; Rozen WM; Orlandi A; Takabe K; Franceschini G; Jerusalem G; Wang X
    Ann Transl Med; 2023 Jan; 11(2):83. PubMed ID: 36819490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer.
    Li X; Tang L; Chen Q; Cheng X; Liu Y; Wang C; Zhu C; Xu K; Gao F; Huang J; Wang R; Guan X
    Chin Med J (Engl); 2022 Oct; 135(20):2436-2445. PubMed ID: 36583862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apatinib enhances the anti-tumor effect of paclitaxel via the PI3K/p65/Bcl-xl pathway in triple-negative breast cancer.
    Chen J; Deng S; Zhang Y; Wang C; Hu X; Kong D; Liang G; Yuan X; Li Y; Wang X
    Ann Transl Med; 2021 Jun; 9(12):1001. PubMed ID: 34277801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines.
    Bräutigam K; Kabore-Wolff E; Hussain AF; Polack S; Rody A; Hanker L; Köster F
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):2923-2933. PubMed ID: 34185141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silencing of COL3A1 represses proliferation, migration, invasion, and immune escape of triple negative breast cancer cells via down-regulating PD-L1 expression.
    Yang F; Lin L; Li X; Wen R; Zhang X
    Cell Biol Int; 2022 Nov; 46(11):1959-1969. PubMed ID: 35930601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target.
    Deng S; Wang M; Wang C; Zeng Y; Qin X; Tan Y; Liang B; Cao Y
    Mol Biol Rep; 2023 Jan; 50(1):577-587. PubMed ID: 36352176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
    De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
    Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1.
    Liu H; Wang Y; Li X; Zhang YJ; Li J; Zheng YQ; Liu M; Song X; Li XR
    Tumour Biol; 2013 Jun; 34(3):1713-22. PubMed ID: 23430586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression.
    Alkaabi D; Arafat K; Sulaiman S; Al-Azawi AM; Attoub S
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
    Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
    Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (-)-Sativan Inhibits Tumor Development and Regulates miR-200c/PD-L1 in Triple Negative Breast Cancer Cells.
    Peng F; Xiong L; Peng C
    Front Pharmacol; 2020; 11():251. PubMed ID: 32231566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer.
    Saleh R; Taha RZ; Sasidharan Nair V; Alajez NM; Elkord E
    Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31349612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
    BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel IGLC2 Gene Linked With Prognosis of Triple-Negative Breast Cancer.
    Chang YT; Tsai WC; Lin WZ; Wu CC; Yu JC; Tseng VS; Liao GS; Hu JM; Hsu HM; Chang YJ; Lin MC; Chu CM; Yang CY
    Front Oncol; 2021; 11():759952. PubMed ID: 35155184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway.
    Hu H; Zhu J; Zhong Y; Geng R; Ji Y; Guan Q; Hong C; Wei Y; Min N; Qi A; Zhang Y; Li X
    Ann Transl Med; 2021 Mar; 9(5):410. PubMed ID: 33842631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment.
    Wu J; Wang W; Gao L; Shao X; Wang X
    Cancer; 2024 Apr; 130(S8):1449-1463. PubMed ID: 38482921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
    Xu S; Sun X; Luo L; Yang Y; Guo Q; Tang S; Jiang Z; Li Y; Han J; Gan W; Yang F; Zhang X; Liu Y; Sun C; He J; Liu M; Zuo D; Zhu W; Wu Y
    Biomed Pharmacother; 2022 Nov; 155():113537. PubMed ID: 36113258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-cancer Drug Anlotinib Promotes Autophagy and Apoptosis in Breast Cancer.
    Chen S; Gao Y; Zhu P; Wang X; Zeng L; Jin Y; Zhi X; Yang H; Zhou P
    Front Biosci (Landmark Ed); 2022 Apr; 27(4):125. PubMed ID: 35468684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models.
    Cheung A; Chenoweth AM; Quist J; Sow HS; Malaktou C; Ferro R; Hoffmann RM; Osborn G; Sachouli E; French E; Marlow R; Lacy KE; Papa S; Grigoriadis A; Karagiannis SN
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.